Abstract
Titanocene dichloride was capable of inhibiting the growth of different types of human tumors in vitro. A total of 14 patients with metastatic renal-cell carcinoma (RCC) received 270 mg/m2 titanocene dichloride every 3 weeks for 6 weeks. Although the toxicities and side effects encountered were mild to moderate, no partial or complete response was detectable. In conclusion, titanocene dichloride has no advantage in the therapy of RCC.
Author information
Authors and Affiliations
Additional information
Received: 18 February 1998 / Accepted: 23 April 1998
Rights and permissions
About this article
Cite this article
Lümmen, G., Sperling, H., Luboldt, H. et al. Phase II trial of titanocene dichloride in advanced renal-cell carcinoma. Cancer Chemother Pharmacol 42, 415–417 (1998). https://doi.org/10.1007/s002800050838
Issue Date:
DOI: https://doi.org/10.1007/s002800050838